Moximed Revenue and Competitors

Moximed® Inc: The Early OA Company Osteoarthritis (OA), the most common form of arthritis, affects an estimated 150 million people worldwide. (1) Also known as degenerative joint disease, OA leads to a breakdown of a joint's cartilage and often results in joint pain and loss of motion. OA commonly affects the knees, hips, hands, or back. The goals of OA treatment include minimizing joint pain, restoring normal activity levels, and slowing disease progression. However, many current therapies are either ineffective or involve highly invasive, joint modifying procedures. Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. (1.)2012 Orthoworld Annual Report.